# A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise

Study · id `cardio:ct-nct06411275` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06411275](<https://clinicaltrials.gov/study/NCT06411275>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06411275

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 113 participants.

## Technical summary

Registry record NCT06411275. Randomized; double masking; primary purpose treatment. Start 2022-03-31 (actual); primary completion 2023-01-17 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 113 participants (enrolled count; ClinicalTrials.gov record NCT06411275, source copy `cardio:ctgov-nct06411275-2026-08-03`, retrieved 2026-10-26)
- Started: 2022-03-31 (actual) (ClinicalTrials.gov record NCT06411275, source copy `cardio:ctgov-nct06411275-2026-08-03`, retrieved 2026-10-26)
- Primary completion: 2023-01-17 (actual) (ClinicalTrials.gov record NCT06411275, source copy `cardio:ctgov-nct06411275-2026-08-03`, retrieved 2026-10-26)
- Completion: 2023-01-17 (actual) (ClinicalTrials.gov record NCT06411275, source copy `cardio:ctgov-nct06411275-2026-08-03`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06411275, source copy `cardio:ctgov-nct06411275-2026-08-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06411275-2026-08-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): HTD1801
- Intervention (Drug): Placebo
- Intervention (Drug): HTD1801
- Lead sponsor: Shenzhen HighTide Biopharmaceutical Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Shenzhen HighTide Biopharmaceutical Ltd. (`cardio:org-shenzhen-hightide-biopharmaceutical-ltd`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Berberine Ursodeoxycholate for the Treatment of Type 2 Diabetes: A Randomized Clinical Trial (`cardio:pubmed-40029660`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fbc720e3c7b4f03d45de5cc6d7dd732110d868d442d00659db1c8fe25419abf7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
